Danaher (NYSE:DHR) Given New $212.00 Price Target at Wells Fargo & Company

22 Apr 2026, 14:26 by Tristan Rich · The Markets Daily

Danaher (NYSE:DHR – Get Free Report) had its price objective lowered by investment analysts at Wells Fargo & Company from $240.00 to $212.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The brokerage presently has an “equal weight” rating on the conglomerate’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 11.03% from the stock’s previous close.

Several other research firms have also recently weighed in on DHR. Robert W. Baird cut their price objective on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday. The Goldman Sachs Group cut their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Rothschild & Co Redburn set a $205.00 target price on Danaher in a research note on Friday, April 17th. Jefferies Financial Group restated a “buy” rating and issued a $245.00 target price on shares of Danaher in a research note on Tuesday. Finally, Leerink Partners upped their price objective on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Eighteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $241.95.

View Our Latest Stock Analysis on Danaher

Danaher Stock Down 1.8%

Shares of NYSE DHR opened at $190.95 on Wednesday. The stock has a market cap of $135.13 billion, a PE ratio of 37.89, a PEG ratio of 2.66 and a beta of 0.95. The business has a fifty day moving average of $197.89 and a two-hundred day moving average of $214.56. Danaher has a 52-week low of $180.03 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.88 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, equities research analysts expect that Danaher will post 8.4 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the transaction, the executive vice president directly owned 5,099 shares in the company, valued at $1,060,642.99. This represents a 20.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Danaher

Institutional investors have recently bought and sold shares of the stock. Elevated Capital Advisors LLC purchased a new stake in Danaher during the 4th quarter valued at about $26,000. Hilton Head Capital Partners LLC purchased a new stake in Danaher during the 4th quarter valued at about $27,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Danaher by 71.6% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 53 shares during the period. JPL Wealth Management LLC purchased a new stake in Danaher during the 3rd quarter valued at about $25,000. Finally, WFA of San Diego LLC purchased a new stake in Danaher during the 2nd quarter valued at about $26,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Q1 EPS beat and guidance lift — Danaher reported $2.06 EPS (above consensus) and raised FY26 EPS guidance to $8.35–8.55, signaling confidence in biotech and life‑sciences momentum; this is the main bullish driver. Danaher beats first-quarter profit estimates on strong bioprocessing demand
Positive Sentiment: Bioprocessing and life‑sciences strength — management highlighted double‑digit momentum in bioprocessing and continued strength in life‑sciences tools, which should support margin expansion and cash generation. Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains
Neutral Sentiment: Investor materials and transcripts available — the company posted a press release, slide deck and a full earnings‑call transcript; useful for modeling segment trends and the acquisition roadmap but no immediate surprise. View Press Release / Slide Deck
Neutral Sentiment: Strategic M&A focus — coverage notes Danaher’s acquisition strategy (including the Masimo-related work) as an important growth lever; strategic but timing and integration risk remain to be tracked. DHR Q1 deep dive: Bioprocessing momentum and acquisition strategy drive mixed start to 2026
Negative Sentiment: Revenue slightly missed estimates — Q1 revenue was $5.95B vs. ~ $6.0B consensus, and that shortfall was cited as a reason for near‑term share weakness. Danaher (NYSE:DHR) Misses Q1 CY2026 Revenue Estimates
Negative Sentiment: Diagnostics and respiratory softness — multiple reports flagged weakness in diagnostics and a lowered respiratory outlook, which could pressure near‑term organic growth until end markets recover. Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock

About Danaher

(Get Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.